[Treatment of recurrent uterine endometrial cancer in adjuvant therapy with medroxyprogesterone acetate (MPA) in addition of etoposide].
In recent years, we treated recurrent uterine endometrial cancer by combined therapy including CDDP. But in poor cases, like renal failure and such, it is difficult to perform the therapy. Two cases of recurrent uterine endometrial cancer treated earlier with MPA were presently treated with an addition of etoposide. The first case was given etoposide (50 mg/m2/day 4 times for 21 days by oral administration). The target tumor mass was reduced in size, occult blood vanished, and the tumor marker was reduced. The other case was treated with etoposide, 50 mg/body/day for 21 days by oral administration, but because of diarrhea, the dose had to be decreased to 25 mg/body/day every day. The tumor marker was reduced and genital bleeding vanished. These cases suggested that etoposide-MPA combined therapy might be effective for recurrent uterine endometrial cancer of well-differentiated type.
Ishizaki
T
T
Dept. of Obstetrics and Gynecology, Gamoucho Hospital.
Yamamoto
T
T
Itoh
R
R
Yasuda
J
J
Fujita
H
H
Okada
H
H
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000284:Administration, Oral; D000368:Aged; D004334:Drug Administration Schedule; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005047:Etoposide / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*
D005047:Etoposide; D017258:Medroxyprogesterone Acetate